![Belgium to accelerate plan for tighter measures; concern over rising Irish cases – as it happened | Coronavirus | The Guardian Belgium to accelerate plan for tighter measures; concern over rising Irish cases – as it happened | Coronavirus | The Guardian](https://i.guim.co.uk/img/media/5855403c853d02a87eb30e043fe761e582f228c0/0_0_6000_4000/master/6000.jpg?width=445&quality=45&auto=format&fit=max&dpr=2&s=664bde7c13b779c3e372a931b4011394)
Belgium to accelerate plan for tighter measures; concern over rising Irish cases – as it happened | Coronavirus | The Guardian
![Belgian employers expect to maintain a very strong hiring pace for the first quarter of 2022 – ManpowerGroup Belgium Belgian employers expect to maintain a very strong hiring pace for the first quarter of 2022 – ManpowerGroup Belgium](https://www.manpowergroup.be/wp-content/uploads/2021/12/05_Historic_NEO_-Outlook_-Belgium_-MEOS_Q122_-BEENG.png)
Belgian employers expect to maintain a very strong hiring pace for the first quarter of 2022 – ManpowerGroup Belgium
![Belgium to accelerate plan for tighter measures; concern over rising Irish cases – as it happened | Coronavirus | The Guardian Belgium to accelerate plan for tighter measures; concern over rising Irish cases – as it happened | Coronavirus | The Guardian](https://i.guim.co.uk/img/media/cb28705132a186089bbc45e2e8a4bde13745a575/215_655_4429_2658/master/4429.jpg?width=620&quality=85&auto=format&fit=max&s=e6f6c2c3851dd34b77444b2a203debff)
Belgium to accelerate plan for tighter measures; concern over rising Irish cases – as it happened | Coronavirus | The Guardian
![A look into the future of the COVID-19 pandemic in Europe: an expert consultation - The Lancet Regional Health – Europe A look into the future of the COVID-19 pandemic in Europe: an expert consultation - The Lancet Regional Health – Europe](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1fd2af73-e037-459f-ba96-f549235bfd93/gr1_lrg.jpg)
A look into the future of the COVID-19 pandemic in Europe: an expert consultation - The Lancet Regional Health – Europe
![Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial - The Lancet Infectious Diseases Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial - The Lancet Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/659172b1-d1c4-4785-a95b-73ed3453ace7/gr1.gif)
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial - The Lancet Infectious Diseases
![A look into the future of the COVID-19 pandemic in Europe: an expert consultation - The Lancet Regional Health – Europe A look into the future of the COVID-19 pandemic in Europe: an expert consultation - The Lancet Regional Health – Europe](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ff136c7a-3fd3-4944-81f6-807df5c1a32a/gr2_lrg.jpg)
A look into the future of the COVID-19 pandemic in Europe: an expert consultation - The Lancet Regional Health – Europe
![Microorganisms | Free Full-Text | Vaccination against Tick-Borne Encephalitis (TBE) in Italy: Still a Long Way to Go | HTML Microorganisms | Free Full-Text | Vaccination against Tick-Borne Encephalitis (TBE) in Italy: Still a Long Way to Go | HTML](https://www.mdpi.com/microorganisms/microorganisms-10-00464/article_deploy/html/images/microorganisms-10-00464-g001.png)
Microorganisms | Free Full-Text | Vaccination against Tick-Borne Encephalitis (TBE) in Italy: Still a Long Way to Go | HTML
![Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d9c88d17-491c-48a9-b36a-38ed9f734eaa/gr1.gif)
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet
![COVID-19 tracker: Omicron variant could cause global surge, WHO says; J&J recipients opt for other boosters | Fierce Pharma COVID-19 tracker: Omicron variant could cause global surge, WHO says; J&J recipients opt for other boosters | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1619703711/GettyImages-1293456793.jpg/GettyImages-1293456793.jpg?VersionId=WB8tj9FiBVgpCnJxtaqj0TT3Gnf4tWIM)
COVID-19 tracker: Omicron variant could cause global surge, WHO says; J&J recipients opt for other boosters | Fierce Pharma
![Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic - The Lancet Regional Health – Europe Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic - The Lancet Regional Health – Europe](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/ffa71d2c-d765-491d-b670-9b8c73b5ac10/gr1.jpg)